



## ***“Wheeze Rate – A New Paradigm in Asthma Management”***

### COMPANY ANNOUNCEMENT

## **KarmelSonix highlights the clinical value proposition of its Products**

**17<sup>th</sup> November, 2010:** The Management of KarmelSonix Ltd. (ASX: KSX) wish to advise that the company, in a series of 5 presentations at the high profile International Convention of the American Thoracic Society (ATS), intends to highlight and reinforce the clinical value proposition of its novel products involving over 390 patients. (A comprehensive list of these presentations can be found on the company’s website at [www.karmelsonix.com](http://www.karmelsonix.com) ).

The studies, carried out in partnership with some of the key opinion leaders (KOLs) in the fields of pulmonology and sleep disorders, highlight the clinical uses of the Company’s core technology and its novel products: the WheezoMeter™, WHolter™ and PulmoTrack®. The groundbreaking studies and their findings are key to the acceptance of the KarmelSonix product offerings as a new gold standard for diagnosis and management of asthma and other upper respiratory disorders by key opinion leaders Worldwide.

The Company is also pleased to report that a number of its clinical studies have recently been granted Ethics Committee approval.

“We are very excited about the positive impact that these high profile studies will have in support of our global sales and marketing initiatives. No doubt, our sales will benefit from these KOL reports going forward”, commented Mr. Ross Haghghat, the Company’s Chairman and Interim CEO.

“These studies not only confirm the value proposition for our novel technology offerings, but they also lay the foundation for new indications that enhance the impact of using our devices on the outcome of asthma, COPD, chronic cough and Cystic Fibrosis patients”, said Dr. Noam Gavriely, the Company Founder and Chief Medical Officer. “This class of studies is in support of our application to the American Medical Association (AMA) for additional CPT (reimbursement) codes that will cover the interpretation of longitudinal testing by the WheezoMeter™,” continued Dr. Gavriely.

“Taking this plan forward is in direct support of our ‘TriPod of Success’ initiative and will generate a critical mass of users who, through interactions among themselves and with colleagues as well as through scientific publications, will help create awareness, acceptance and incorporation of the ARM (Acoustic Respiratory Monitoring) technology into mainstream clinical practice,” said Mr. Haghghat.

Importantly, the studies referred to below are part of the ongoing product post registration work that the Company has been and continues to carry out in order to validate the utility of the KSX products. The trials are being carried out in major hospitals in key cities and have input from Key Opinion Leaders in the respiratory field.

## ***“Wheeze Rate – A New Paradigm in Asthma Management”***

<b>KarmelSonix Ltd. (KSX)</b> Suite 2, 1233 High Street Armadale VIC 3143 Australia	<b>KarmelSonix (Israel) Ltd.</b> Suite 2.03, 25 Solent Circuit Norwest Business Park, Baulkham Hills NSW 2153 Australia	<b>KarmelSonix (Israel) Ltd.</b> 16 Palyam Avenue Haifa, 33095 Israel	<b>KarmelSonix USA.</b> 8599 Haven Avenue Alta Loma, CA 91701 USA
--	---	--	--

## **“Wheeze Rate – A New Paradigm in Asthma Management”**

**A listing of the planned presentations is noted below:**

**Acoustic Respiratory Monitoring as an adjunct to Polysomnography in a Sleep Laboratory**

**Principal Investigator:** Dr. Jeremy M Goldin  
**Institution:** Royal Melbourne Hospital  
**Number of Patients:** 69 Patients

**Comparison of Wheeze Rate in Patients with Physician-Auscultated Wheeze/Stridor, Obstructed Spirometry, and Normal Spirometry and Exam**

**Principal Investigator:** Dr. Oren Lakser  
**Institution:** Children’s Hospital of Wisconsin Clinic  
**Number of Patients:** 118 Paediatric Patients

**Ambient and Chest Confined Wheezing and Extreme FEV1 Drop Post Exercise in a 17 Year Old Asthmatic with Exercise-Induced Shortness of Breath (SOB): A Case Report**

**Principal Investigator:** Dr. Oren Lakser  
**Institution:** Children’s Hospital of Wisconsin Clinic  
**Number of Patients:** Paediatric Single Patient

**Do Wheezometry, Spirometry and Symptoms Correlate in Asthma Patients Who Are Not Well-Controlled?**

**Principal Investigator:** Dr. Ricardo Tan and Prof. Simon Godfrey  
**Institution:** California Allergy & Asthma Medical Group  
**Number of Patients:** Paediatric Single Patient

**Wheezes, Rhonchi and Whistles are Acoustically Distinct, Yet All are Manifestations of Airflow through Constricted Pulmonary Airways**

**Principal Investigator:** Prof. Noam Gavriely and Prof. Simon Godfrey  
**Institution:** KarmelSonix, Ltd.  
**Number of Patients:** 150 adult and Paediatric Patients and 50 normal controls

**For additional information please contact:**

Mr. Ross Haghghat + 1 978 375 0085 [Rhaghghat@tritonsys.com](mailto:Rhaghghat@tritonsys.com)  
 Prof. Noam Gavriely +972-544-661337 [Noam@karmelsonix.com](mailto:Noam@karmelsonix.com)

**About KarmelSonix :** KarmelSonix Ltd focuses on supplying innovative non-invasive acoustic tools for disease management of asthma and related pulmonary disorders. Asthma affects 6-16% of the population in developed countries with a cost exceeding \$US15 billion in the US alone.

Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all ages, including the very young, very old and others who cannot perform currently available tests. The technology that comes from extensive R&D and clinical validation in the US, Israel and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during sleep. The company is now focussing its efforts on early commercialization of its products particularly in the AsiaPac, European and North American markets.

## **“Wheeze Rate – A New Paradigm in Asthma Management”**

<p style="text-align: center;"><b>KarmelSonix Ltd. (KSX)</b></p> <p>Suite 2, 1233 High Street          Armadale VIC 3143          Australia</p>	<p style="text-align: center;"><b>KarmelSonix (Israel) Ltd.</b></p> <p>Suite 2.03, 25 Solent Circuit          Norwest Business Park,          Baulkham Hills NSW 2153          Australia</p>	<p style="text-align: center;"><b>KarmelSonix USA.</b></p> <p>16 Palyam Avenue          Haifa, 33095          Israel</p>	<p style="text-align: center;"><b>KarmelSonix USA.</b></p> <p>8599 Haven Avenue          Alta Loma, CA 91701          USA</p>
---	--	--	---